- Home
- TURN vs KPTI Comparison
TURN vs KPTI Comparison
Compare TURN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- KPTI
- Stock Information
- Founded
- TURN 1981
- KPTI 2008
- Country
- TURN United States
- KPTI United States
- Employees
- TURN N/A
- KPTI N/A
- Industry
- TURN Finance/Investors Services
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- KPTI Health Care
- Exchange
- TURN Nasdaq
- KPTI Nasdaq
- Market Cap
- TURN 46.3M
- KPTI 44.5M
- IPO Year
- TURN N/A
- KPTI 2013
- Fundamental
- Price
- TURN $4.98
- KPTI $7.11
- Analyst Decision
- TURN
- KPTI Buy
- Analyst Count
- TURN 0
- KPTI 6
- Target Price
- TURN N/A
- KPTI $39.80
- AVG Volume (30 Days)
- TURN 22.0K
- KPTI 218.0K
- Earning Date
- TURN 02-26-2018
- KPTI 08-11-2025
- Dividend Yield
- TURN N/A
- KPTI N/A
- EPS Growth
- TURN N/A
- KPTI N/A
- EPS
- TURN 0.30
- KPTI N/A
- Revenue
- TURN $488,011.00
- KPTI $137,269,000.00
- Revenue This Year
- TURN N/A
- KPTI $3.67
- Revenue Next Year
- TURN N/A
- KPTI $9.40
- P/E Ratio
- TURN $16.69
- KPTI N/A
- Revenue Growth
- TURN 254.25
- KPTI N/A
- 52 Week Low
- TURN $3.12
- KPTI $3.51
- 52 Week High
- TURN $4.98
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- TURN 81.01
- KPTI 66.00
- Support Level
- TURN $4.51
- KPTI $6.02
- Resistance Level
- TURN $4.74
- KPTI $8.15
- Average True Range (ATR)
- TURN 0.12
- KPTI 0.74
- MACD
- TURN 0.04
- KPTI 0.24
- Stochastic Oscillator
- TURN 100.00
- KPTI 76.42
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.